Lv61
2580 积分 2023-05-06 加入
Factors reducing omalizumab response in severe asthma
3个月前
已完结
The standardized and mini versions of the PAQLQ are valid, reliable, and responsive measurement tools
3个月前
已完结
Tuberous sclerosis
7个月前
已完结
Bidirectional interaction of airway epithelial remodeling and inflammation in asthma
10个月前
已完结
Might biologics serve to interrupt the atopic march?
11个月前
已完结
Total immunoglobulin E in infant bronchiolitis and risk of developing asthma
11个月前
已完结
[Clinical efficacy observation of omalizumab on patients with moderate to severe allergic asthma for one year]
1年前
已完结
Omalizumab in CSU: Real-Life Experience in Dose/Interval Adjustments and Treatment Discontinuation
1年前
已完结
An Update on Monoclonal Antibody Therapy to Treat Moderate-to-Severe Asthma: Benefits, Choices, and Limitations
1年前
已完结
皖公网安备34019202002308
